Navigation Links
Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
Date:10/12/2009

CAMBRIDGE, England, October 12 /PRNewswire/ -- Crescendo Biologics ("Crescendo") today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

Crescendo brings together highly innovative in vivo and in vitro technology platforms invented by scientists at the Babraham Institute, including Dr Marianne Bruggemann, a pioneer in the development of human antibody transgenics, and Dr Mike Taussig, an expert in protein display and array systems. Crescendo's technology platforms will enable the Company to generate diverse, stable and optimised human heavy chain (VH) fragments, the smallest functional binding units of an antibody molecule. These fragments offer several advantages as starting points for the development of novel therapeutics: they can be administered topically by inhaled and oral routes as well as by injection; they provide great flexibility in format of the product, including bi-specific targeting; they are easy to manufacture and stable; and they have the potential to target binding sites inaccessible to conventional antibodies.

The Crescendo transgenic mouse platform has the potential to rapidly and predictably generate human VH fragments that have high affinity and solubility, and no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages in antibody optimisation.

The seed funding will allow Crescendo to advance the development of these platforms and to initiate the development of proprietary therapeutics, following the appointment of the CSO, Dr Mike Romanos, who has extensive experience in biopharmaceutical R&D and played a pivotal role in building GlaxoSmithKline's antibody
'/>"/>

SOURCE Crescendo Biologics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
2. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
3. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
4. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
5. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
6. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
7. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
8. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
9. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
10. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
11. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an early ... is very pleased to announce that the Musculoskeletal Transplant ... agreed to invest in their seed round of development ... tissue storage capabilities. AmnioChor,s technology allows ... the human stem cells living within those tissues. Amnion ...
(Date:7/29/2015)... England , July 29, 2015  Indivior PLC ... (NDA) for naloxone nasal spray was accepted and received ... (FDA) for the treatment of opioid overdose. This naloxone ... naloxone specially formulated for optimal absorption into the nasal ... require minimal training so individuals may be better equipped ...
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Aug. 26 Bio-Reaction Industries is,pleased to announce ... executive,David Skiven as the newest member on their ... environmentally responsible innovations that Mr.,Skiven oversaw during his ... Group at GM, it,s logical that he would ...
... for Biopharmaceutical, Cell,Culture, Life Science Research and Diagnostics Industry Adds ... Productivity, ... Safety and Time to Market, FORT ... global supplier of animal free,products that enhance productivity, safety and ...
... NEEDHAM, Massachusetts, August 26 /PRNewswire-FirstCall/,-- Oridion Systems ... agreement with,Spacelabs Healthcare, a leading global medical ... now employs Oridion Microstream(R),capnography technology in its ... Spacelabs Healthcare, recognizing the importance of ...
Cached Biology Technology:GM Exec Joins Bio-Reaction Industries' Board of Directors 2InVitria Expands Sales Team 2InVitria Expands Sales Team 3Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 2Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 3Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 4
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Knut Stamnes, Professor and Department Director of Physics ... has been awarded a NASA grant for work ... satellite. His proposal to "use and further develop ... coupled atmosphere-surface systems" is funded as part of ...
... Senior Design team at Stevens Institute of Technology is ... arise during thoracic surgeries. Five undergraduate Biomedical Engineering students ... of existing catheter design and introduces a potentially profitable ... the efforts of the Stevens Innovative Fluid Extraction System ...
... revealing how age-old irrigation techniques may have boosted the ... an estimated 200 million people today. ... kingdom that was located in present-day Sudan, provides details ... disease across populations in ancient times, and how human ...
Cached Biology News:Dr. Knut Stamnes at Stevens receives NASA grant for environmental monitoring 2Dr. Knut Stamnes at Stevens receives NASA grant for environmental monitoring 3Stevens thoracic catheter senior design team takes 1st place at regional ISPE competition 2Stevens thoracic catheter senior design team takes 1st place at regional ISPE competition 3Mummies tell history of a 'modern' plague 2Mummies tell history of a 'modern' plague 3
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
... smooth muscle cell specific protein, is reported to ... such as intestine, lung and uterus. It shares ... alpha expression has been reported in most tissues ... visceral forms. It is also reported to be ...
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Request Info...
Biology Products: